RANIBIZUMAB ( DrugBank: Ranibizumab )
4 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 34 | 神経線維腫症 | 1 |
| 166 | 弾性線維性仮性黄色腫 | 4 |
| 227 | オスラー病 | 1 |
| 301 | 黄斑ジストロフィー | 1 |
34. 神経線維腫症
臨床試験数 : 133 / 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00657202 (ClinicalTrials.gov) | March 2008 | 27/3/2008 | Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 | Pilot Study of Ranibizumab (Lucentis) for Neurofibromas Associated With Neurofibromatosis 1 | Neurofibromatosis Type 1;Cutaneous Neurofibromas | Drug: Ranibizumab | Massachusetts General Hospital | NULL | Completed | 18 Years | N/A | Both | 11 | Phase 0 | United States |
166. 弾性線維性仮性黄色腫
臨床試験数 : 16 / 薬物数 : 27 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-001421-55-FR (EUCTR) | 13/06/2013 | 22/09/2015 | An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSE | An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSE | Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Retinal Vein Occlusion (RVO) or Diabetic macular edema (DME) and other ocular neovascularization and/or complication such as Rubeosis Iridis and Neovacular Glaucoma and Proliferative Diabetic Retinopathy requiring Vitrectomy MedDRA version: 18.0;Level: HLGT;Classification code 10047060;Term: Retina, choroid and vitreous haemorrhages and vascular disorders;System Organ Class: 10015919 - Eye disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: Lucentis Product Name: Lucentis Product Code: RFB002A INN or Proposed INN: RANIBIZUMAB | Novartis Pharma S.A.S | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 3 | France | ||
| 2 | NCT00510965 (ClinicalTrials.gov) | August 2007 | 1/8/2007 | Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE) | Ranibizumab in Choroidal Neovascularization (CNV) Due to Pseudoxanthoma Elasticum (PXE, Groenblad-Strandberg-Syndrome) | Choroidal Neovascularization | Drug: Intravitreal injection ranibizumab | University Hospital, Bonn | Novartis | Completed | 18 Years | 65 Years | Both | 10 | Phase 2 | Germany |
| 3 | EUCTR2006-006231-49-DE (EUCTR) | 24/07/2007 | 06/03/2007 | Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06 | Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06 | Pseudoxanthoma elasticum (PXE) is an inherited systemic disease characterized by changes in the elastic tissue. Pseudoxanthoma elasticum mainly affects the skin, eyes, heart, and GI system. The cutaneous and ocular findings of PXE are referred to as Grönblad-Strandberg syndrome. Pseudoxanthoma elasticum may be autosomal dominant or autosomal recessive. In Pseudoxanthoma elasticum, choroidal nevoscualrization (CNV) is a frequently occuring complication in late stage disease MedDRA version: 8.1;Level: LLT;Classification code 10037150;Term: Pseudoxanthoma elasticum | Trade Name: Lucentis Product Name: Lucentis Product Code: RFB002 INN or Proposed INN: ranibizumab Other descriptive name: RFB002, rhuFab V2 | Department of Ophthalmology, Bonn University | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Germany | ||
| 4 | NCT00470977 (ClinicalTrials.gov) | May 2007 | 4/5/2007 | Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy | Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection) | Coats' Disease;Idiopathic Retinal Telangiectasia;Retinal Angiomatous Proliferation;Polypoidal Choroidal Vasculopathy;Pseudoxanthoma Elasticum;Pathological Myopia;Multi-focal Choroiditis;Rubeosis Iridis;Von Hippel Lindau Disease;BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder) | Drug: ranibizumab injection (0.5 mg) | Manhattan Eye, Ear & Throat Hospital | Genentech, Inc. | Completed | 18 Years | N/A | Both | 18 | Phase 1/Phase 2 | United States |
227. オスラー病
臨床試験数 : 56 / 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01406639 (ClinicalTrials.gov) | July 2011 | 29/7/2011 | Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Ranibizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT);Nosebleeds | Drug: Ranibizumab | University of California, San Diego | Genentech, Inc. | Withdrawn | 18 Years | N/A | Both | 0 | Phase 1 | United States |
301. 黄斑ジストロフィー
臨床試験数 : 46 / 薬物数 : 42 - (DrugBank : 11) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00470977 (ClinicalTrials.gov) | May 2007 | 4/5/2007 | Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy | Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection) | Coats' Disease;Idiopathic Retinal Telangiectasia;Retinal Angiomatous Proliferation;Polypoidal Choroidal Vasculopathy;Pseudoxanthoma Elasticum;Pathological Myopia;Multi-focal Choroiditis;Rubeosis Iridis;Von Hippel Lindau Disease;BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder) | Drug: ranibizumab injection (0.5 mg) | Manhattan Eye, Ear & Throat Hospital | Genentech, Inc. | Completed | 18 Years | N/A | Both | 18 | Phase 1/Phase 2 | United States |